<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Passive immunotherapy with plasma derived from patients convalescent from SARS-CoV-2" exact="infection" post="can be a promising approach in the treatment of"/>
 <result pre="in the treatment of COVID-19 patients. It is important that" exact="Blood" post="Establishments are prepared to satisfy requests for immune plasma"/>
 <result pre="with plasma derived from patients that have recovered from SARS-CoV-2" exact="infection" post="can be a promising approach in the treatment of"/>
 <result pre="the prognosis of patients affected by severe forms of the" exact="disease" post="and we cannot exclude a rapid and sustained increase"/>
 <result pre="increase could be even more pronounced in case of a" exact="limited" post="access to other therapeutic options due to the possible"/>
 <result pre="authorities [12]). Therefore, it is now of utmost importance that" exact="Blood" post="Establishments are prepared to satisfy requests for â€œhyperimmune plasmaâ€�"/>
 <result pre="focused, at present, on patients with a very recent documented" exact="infection" post="by SARS-CoV-2 who volunteer, upon informed consent, to undergo"/>
 <result pre="procedures to collect plasma specifically intended for therapy of severe" exact="infections" post="by SARS-CoV-2. This target population requires some caution because"/>
 <result pre="collected by apheresis from patients recently recovered from laboratory confirmed" exact="infection" post="by SARS-CoV-2 (either hospitalised or self-isolated at home) with"/>
 <result pre="large number of people who have recovered from an asymptomatic" exact="infection" post="(or from a disease with minor clinical signs); many"/>
 <result pre="who have recovered from an asymptomatic infection (or from a" exact="disease" post="with minor clinical signs); many among them are probably"/>
 <result pre="contribute to havinga deeper insight into the epidemiology of the" exact="disease" post="outside the context of a severe clinical disease leading"/>
 <result pre="of the disease outside the context of a severe clinical" exact="disease" post="leading to hospitalisation of patients. 3 Standard for the"/>
 <result pre="On each plasma unit it is advisable to determine the" exact="total" post="content of immunoglobulins (IgG, IgA e IgM) and neutralizing"/>
 <result pre="saturation â‰¤93 % -tracheal intubation with mechanical ventilation -Sequential Organ" exact="Failure" post="Assessment (SOFA) score -ICU length of stay -Hospital length"/>
 <result pre="of transfusion associated circulatory overload. 4.3 Time for administration An" exact="early onset" post="of the therapy with immune plasma: the optimal period"/>
 <result pre="other drugs used in the treatment of COVID-19. In the" exact="absence of" post="any conclusion, immune plasma can be administered on the"/>
 <result pre="also take place in treatment with this product; in particular" exact="Blood" post="Establishments should remind treating physicians of: -the absolute contraindication"/>
 <result pre="absolute contraindication of administering human plasma to patients with a" exact="complete" post="IgA deficit (we recommend to test for IgA before"/>
 <result pre="clinical use of plasma. 5 Final recommendations We recommend that" exact="Blood" post="Establishments obtain an informed consent from blood donors in"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis2112015809025030060"/>
 <result pre="&amp;amp; HealthCareGuide to the Preparation, use and Quality Assurance of" exact="Blood" post="Components19th ed.2017EDQM) Council of EuropeAvailable at:Accessed on: 30/03/2020https://www.edqm.eu/sites/default/files/list_of_contents_19th_ed-blood-quality.pdf 15Soo"/>
 <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocolSpringerplus4201570926618098 17ChengY.WongR.SooY.O.Use of convalescent"/>
 <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocolSpringerplus4201570926618098 17ChengY.WongR.SooY.O.Use of convalescent plasma"/>
 <result pre="in Hong KongEur J Clin Microbiol Infect Dis242005444615616839 18DuangJ.HanX.BaiL.Assessment of" exact="heart" post="rate, acidosis, consciousness, oxygenation, and respiratory rate to predict"/>
 <result pre="Infect Dis242005444615616839 18DuangJ.HanX.BaiL.Assessment of heart rate, acidosis, consciousness, oxygenation, and" exact="respiratory" post="rate to predict noninvasive ventilation failure in hypoxemic patientsIntensive"/>
 <result pre="failure in hypoxemic patientsIntensive Care Med43201719219927812731 19WHOUse of Convalescent Whole" exact="Blood" post="or Plasma Collected from Patients Recovered from Ebola Virus"/>
 <result pre="Whole Blood or Plasma Collected from Patients Recovered from Ebola" exact="Virus Disease" post="for Transfusion, as an Empirical Treatment During Outbreaks2014http://apps.who.int/iris/rest/bitstreams/604045/retrieve 20CroweJ.E.Jr.FirestoneC.Y.MurphyB.R.Passively"/>
 <result pre="Blood or Plasma Collected from Patients Recovered from Ebola Virus" exact="Disease" post="for Transfusion, as an Empirical Treatment During Outbreaks2014http://apps.who.int/iris/rest/bitstreams/604045/retrieve 20CroweJ.E.Jr.FirestoneC.Y.MurphyB.R.Passively"/>
 <result pre="Disease for Transfusion, as an Empirical Treatment During Outbreaks2014http://apps.who.int/iris/rest/bitstreams/604045/retrieve 20CroweJ.E.Jr.FirestoneC.Y.MurphyB.R.Passively" exact="acquired" post="antibodies suppress humoral but not cell-mediated immunity in mice"/>
 <result pre="but not cell-mediated immunity in mice immunized with live attenuated" exact="respiratory" post="syncytial virus vaccinesJ Immunol16720013910391811564809 This article has been published"/>
 <result pre="syncytial virus vaccinesJ Immunol16720013910391811564809 This article has been published in" exact="Blood" post="Transfusion DOI 10.2450 / 2020.0124âˆ’20 and at the request"/>
 <result pre="Readers should cite the article of the first publication in" exact="Blood" post="Transfusion."/>
</results>
